Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Profit After Tax (2016 - 2026)

Perspective Therapeutics' Profit After Tax history spans 17 years, with the latest figure at -$26.2 million for Q1 2026.

  • On a quarterly basis, Profit After Tax fell 44.08% to -$26.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$111.1 million, a 30.48% decrease, with the full-year FY2025 number at -$103.1 million, down 30.07% from a year prior.
  • Profit After Tax hit -$26.2 million in Q1 2026 for Perspective Therapeutics, up from -$37.5 million in the prior quarter.
  • Over the last five years, Profit After Tax for CATX hit a ceiling of -$371000.0 in Q1 2023 and a floor of -$40.2 million in Q4 2024.
  • Historically, Profit After Tax has averaged -$15.9 million across 5 years, with a median of -$12.3 million in 2024.
  • Biggest five-year swings in Profit After Tax: soared 72.46% in 2023 and later tumbled 3211.05% in 2024.
  • Tracing CATX's Profit After Tax over 5 years: stood at -$7.3 million in 2022, then plummeted by 236.4% to -$24.7 million in 2023, then tumbled by 62.79% to -$40.2 million in 2024, then rose by 6.67% to -$37.5 million in 2025, then surged by 30.14% to -$26.2 million in 2026.
  • Business Quant data shows Profit After Tax for CATX at -$26.2 million in Q1 2026, -$37.5 million in Q4 2025, and -$26.0 million in Q3 2025.